

Supporting information for Activation of a G protein-coupled receptor through indirect antibody-mediated tethering of ligands

Cheloha *et al*

Antibody	Manufacturer	Clone	Cat No.
Mouse anti- HLA-A,B,C	Biolegend, San Diego, CA, USA	W6/32	311402
Mouse anti- CD63	Abcam, Cambridge, MA, USA	MEM-259	Ab8219
Mouse anti- GFP	RnD Systems, Minneapolis, MN, USA	#454505	MAB42401-R
Rabbit-anti MHC1	Cell Signaling Technologies	Polyclonal	12851
Mouse anti-CD81	RnD Systems, Minneapolis, MN, USA	#454720	MAB4615

Supporting Table 1. Commercial antibodies used in this study.

Conjugate or peptide	m/z observed	m/z calculated
VHH _{MHC-II}	15620	n/a
VHH _{6E}	13479	n/a
VHH _{MHC-I}	14445	n/a
VHH _{rlg}	14525	n/a
VHH _{GFP}	14215	n/a
VHH _{mlg}	15162	n/a
VHH _{α5β1}	15016	n/a
VHH _{MHC-II} -biotin-azide	15492	15492
VHH _{6E} -biotin-azide	13333	13461
VHH _{MHC-I} -biotin-azide	14300	14428
VHH _{rlg} -biotin-azide	14374	14502
VHH _{GFP} -biotin-azide	14080	14208
VHH _{mlg} -biotin-azide	15012	15140
VHH _{α5β1} -biotin-azide	14875	15003
VHH _{6E} -PTH ₁₋₁₁	15165	15172.3
VHH _{MHC-I} -PTH ₁₋₁₁	16140	16139.3
VHH _{rlg} -PTH ₁₋₁₁	16214	16213.3
VHH _{GFP} -PTH ₁₋₁₁	15920	15919.3
VHH _{mlg} -PTH ₁₋₁₁	16852	16851.3
VHH _{α5β1} -PTH ₁₋₁₁	16718	16714.3
VHH _{MHC-II} -PTH ₁₋₃₄	20346	20339.7
VHH _{GFP} -PTH ₁₋₃₄	18910	18927.7
PTH(1-11)-dbco	1839.3	
PTH(1-34)-PEG3-dbco	4847.7	
PTH(1-11)-Cys	1411.2	

Supporting Table 2: Summary of mass spectrometric characterization of VHH-PTH conjugates.

hPTHR1	MGTARIAPGL	ALLLCCPVLS	SAYALVDADD	VMTKEEQIFL	LHRAQAQCEK
hPTHR1-GFP	MGTARIAPGL	ALLLCCPVLS	SAYALVDADD	VMTKEEQIFL	LHRAQAQCEK
rPTHR1-delNT26-181_	MGAARIAPSL	ALLLCCPVLS	SAYAL.....	~~~~~	~~~~~
rPTHR1-delNT-HA	MGAARIAPSL	ALLLCCPVLS	SAY...PYD	VPDYAGGGG.	~~~~~
hPTHR1_6E	MGTARIAPGL	ALLLCCPVLS	SAYALVDADD	VMTKEEQIFL	LHRAQAQCEK
	51				100
hPTHR1	RLKEVLQRP	SIMESDKGWT	SASTSGKPRK	DKASGKLYPE	SEED.....
hPTHR1-GFP	RLKEVLQRP	SIMESDKGWT	SASTSGKPRK	DKASGKLYPE	SEEDKMSKGE
rPTHR1-delNT26-181_	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
rPTHR1-delNT-HA	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
hPTHR1_6E	RLKEVLQRP	SIMESDKGWT	QADQEAKELA	RQISGKLYPE	SEED~~~~~
	101				150
hPTHR1
hPTHR1-GFP	ELFTGVVPIL	VELDGDVNGH	KFSVSGEGEG	DATYGKLTLLK	FICTTGKLPV
rPTHR1-delNT26-181_	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
rPTHR1-delNT-HA	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
hPTHR1_6E	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
	151				200
hPTHR1
hPTHR1-GFP	PWPTLVTTLS	YGVQCFSRYP	DHMKQHDFFK	SAMPEGYVQE	RTIFFKDDGN
rPTHR1-delNT26-181_	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
rPTHR1-delNT-HA	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
hPTHR1_6E	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
	201				250
hPTHR1
hPTHR1-GFP	YKTRAEVKFE	GDTLVNRIEL	KGIDFKEDGN	ILGHKLEYNY	NEHLVYIMAD
rPTHR1-delNT26-181_	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
rPTHR1-delNT-HA	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
hPTHR1_6E	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
	251				300
hPTHR1
hPTHR1-GFP	KQKNGTKAIF	QVHHNIEDGS	VQLADHYQQN	TPIGDGPVLL	PDNHYLHTQS
rPTHR1-delNT26-181_	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
rPTHR1-delNT-HA	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
hPTHR1_6E	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
	301				350
hPTHR1
hPTHR1-GFP	ALSKDPNEKR	DHMLLEFVT	AAGITHGMD	LYKEAPTGS	YRGRPCLPEW
rPTHR1-delNT26-181_	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
rPTHR1-delNT-HA	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
hPTHR1_6E	~~~~~	~~~~~	~~~~~	~KEAPTGS	YRGRPCLPEW
	351				400
hPTHR1	DHILCWPLGA	PGEVVAVPCP	DIYDFNHKG	HAYRRCDRNG	SWELVPGHNR
hPTHR1-GFP	DHILCWPLGA	PGEVVAVPCP	DIYDFNHKG	HAYRRCDRNG	SWELVPGHNR
rPTHR1-delNT26-181_	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
rPTHR1-delNT-HA	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
hPTHR1_6E	DHILCWPLGA	PGEVVAVPCP	DIYDFNHKG	HAYRRCDRNG	SWELVPGHNR
	401				450
hPTHR1	TWANYSECVK	FLTNETRERE	VFDRLGMIYT	VGYSVSLASL	TVAVLILAYF
hPTHR1-GFP	TWANYSECVK	FLTNETRERE	VFDRLGMIYT	VGYSVSLASL	TVAVLILAYF
rPTHR1-delNT26-181_	~~~~~E	VFDRLGMIYT	VGYSMSLASL	TVAVLILAYF
rPTHR1-delNT-HA	~~~~~E	VFDRLGMIYT	VGYSMSLASL	TVAVLILAYF
hPTHR1_6E	TWANYSECVK	FLTNETRERE	VFDRLGMIYT	VGYSVSLASL	TVAVLILAYF

```

451                                     500
hPTHR1      RRLHCTRNYI  HMHLFLSFML  RAVSIFVKDA  VLYSGATLDE  AERLTEEEELR
hPTHR1-GFP  RRLHCTRNYI  HMHLFLSFML  RAVSIFVKDA  VLYSGATLDE  AERLTEEEELR
rPTHR1-delNT26-181_  RRLHCTRNYI  HMHLFLSFML  RAASIFVKDA  VLYSGFTLDE  AERLTEEEELH
rPTHR1-delNT-HA  RRLHCTRNYI  HMHLFLSFML  RAASIFVKDA  VLYSGFTLDE  AERLTEEEELH
hPTHR1_6E   RRLHCTRNYI  HMHLFLSFML  RAVSIFVKDA  VLYSGATLDE  AERLTEEEELR

501                                     550
hPTHR1      AIAQAPPPPA  TAAAGYAGCR  VAVTFFLYFL  ATNYYWILVE  GLYLHSLIFM
hPTHR1-GFP  AIAQAPPPPA  TAAAGYAGCR  VAVTFFLYFL  ATNYYWILVE  GLYLHSLIFM
rPTHR1-delNT26-181_  AIAQVPPPPA  AAAVGYAGCR  VAVTFFLYFL  ATNYYWILVE  GLYLHSLIFM
rPTHR1-delNT-HA  AIAQVPPPPA  AAAVGYAGCR  VAVTFFLYFL  ATNYYWILVE  GLYLHSLIFM
hPTHR1_6E   AIAQAPPPPA  TAAAGYAGCR  VAVTFFLYFL  ATNYYWILVE  GLYLHSLIFM

551                                     600
hPTHR1      AFFSEKKYLW  GFTVFGWGLP  AVFVAVVWSV  RATLANTGCW  DLSSGNKKWI
hPTHR1-GFP  AFFSEKKYLW  GFTVFGWGLP  AVFVAVVWSV  RATLANTGCW  DLSSGNKKWI
rPTHR1-delNT26-181_  AFFSEKKYLW  GFTIFGWGLP  AVFVAVVWGV  RATLANTGCW  DLSSGHKKWI
rPTHR1-delNT-HA  AFFSEKKYLW  GFTIFGWGLP  AVFVAVVWGV  RATLANTGCW  DLSSGHKKWI
hPTHR1_6E   AFFSEKKYLW  GFTVFGWGLP  AVFVAVVWSV  RATLANTGCW  DLSSGNKKWI

601                                     650
hPTHR1      IQVPILASIV  LNFILFINIV  RVLATKLRET  NAGRCDTRQQ  YRKLLKSTLV
hPTHR1-GFP  IQVPILASIV  LNFILFINIV  RVLATKLRET  NAGRCDTRQQ  YRKLLKSTLV
rPTHR1-delNT26-181_  IQVPILASIV  LNFILFINII  RVLATKLRET  NAGRCDTRQQ  YRKLLRSTLV
rPTHR1-delNT-HA  IQVPILASIV  LNFILFINII  RVLATKLRET  NAGRCDTRQQ  YRKLLRSTLV
hPTHR1_6E   IQVPILASIV  LNFILFINIV  RVLATKLRET  NAGRCDTRQQ  YRKLLKSTLV

651                                     700
hPTHR1      LMPLFGVHYI  VFMATPYTEV  SGTLWQVQMH  YEMLFNSFQG  FFWAIYCF
hPTHR1-GFP  LMPLFGVHYI  VFMATPYTEV  SGTLWQVQMH  YEMLFNSFQG  FFWAIYCF
rPTHR1-delNT26-181_  LVPLFGVHYT  VFMALPYTEV  SGTLWQIQMH  YEMLFNSFQG  FFWAIYCF
rPTHR1-delNT-HA  LVPLFGVHYT  VFMALPYTEV  SGTLWQIQMH  YEMLFNSFQG  FFWAIYCF
hPTHR1_6E   LMPLFGVHYI  VFMATPYTEV  SGTLWQVQMH  YEMLFNSFQG  FFWAIYCF


701                                     750
hPTHR1      NGEVQAEIKK  SWSRWTLALD  FKRKARSGSS  SYSYGPVMSH  TSVTNVGP
hPTHR1-GFP  NGEVQAEIKK  SWSRWTLALD  FKRKARSGSS  SYSYGPVMSH  TSVTNVGP
rPTHR1-delNT26-181_  NGEVQAEIRK  SWSRWTLALD  FKRKARSGSS  SYSYGPVMSH  TSVTNVGP
rPTHR1-delNT-HA  NGEVQAEIRK  SWSRWTLALD  FKRKARSGSS  SYSYGPVMSH  TSVTNVGP
hPTHR1_6E   NGEVQAEIKK  SWSRWTLALD  FKRKARSGSS  SYSYGPVMSH  TSVTNVGP

751                                     800
hPTHR1      GLGLPLSPRL  LPTATTNGHP  QLPGHAKPGT  PALETLETT  PAMAAPKDD
hPTHR1-GFP  GLGLPLSPRL  LPTATTNGHP  QLPGHAKPGT  PALETLETT  PAMAAPKDD
rPTHR1-delNT26-181_  GLSLPLSPRL  P. PATTNHGS  QLPGHAKPGA  PATET.ETL  VTMAVPKDD
rPTHR1-delNT-HA  GLSLPLSPRL  P. PATTNHGS  QLPGHAKPGA  PATET.ETL  VTMAVPKDD
hPTHR1_6E   GLGLPLSPRL  LPTATTNGHP  QLPGHAKPGT  PALETLETT  PAMAAPKDD


801                                     832
hPTHR1      FLNGSCSGLD  EEASGPERPP  ALLQEEWETV  M*
hPTHR1-GFP  FLNGSCSGLD  EEASGPERPP  ALLQEEWETV  M*
rPTHR1-delNT26-181_  FLNGSCSGLD  EEASGSARPP  PLLQEGWETV  M*
rPTHR1-delNT-HA  FLNGSCSGLD  EEASGSARPP  PLLQEGWETV  M*
hPTHR1_6E   FLNGSCSGLD  EEASGPERPP  ALLQEEWETV  M*

```

Supporting Figure 1. Sequence alignment of PTHR1 constructs used in this study. Alignment was performed using ClustalOmega. Constructs for hPTHR1 GFP¹, rat PTHR1 lacking extracellular domain residues 26-181 (rPTHR1-delNT26-181)², and rat PTHR1 lacking extracellular domain residues 26-181 with HA-tag incorporated (rPTHR1-delINT-HA)³ were described previously. The GFP insert is shown in green and the HA tag in blue. Residues 1-22 in hPTHR1 correspond to the signal peptide.



Supporting Figure 2. Targeting PTHR1 lacking extracellular domain. HEK293 cells stably expressing cAMP-responsive luciferase were transiently transfected with either rat PTHR1 lacking extracellular domain (rPTH1-delINT) or a construct with an HA tag inserted in place of the extracellular domain (rPTH1-delINT-HA). See below for sequences. **(a)** Schematic of receptor constructs and targeting strategy. **(b)** Representative dose-response curves (one of four independent experiments) for cells transfected with rPTH1-delINT. Data points represent mean \pm SD. X-axis concentrations refer to that of VHH-PTH constructs. Lines on the graph are not from the fitting of a model and only serve to guide the eye. PTH₁₋₁₁ is the same sequence as listed in Figure 2a. The sequence of M-PTH(1-11) in this assay is YVUELQLMHQX where Y is 1-aminocyclopentane-1-carboxylic acid, U is Aib, and X is homoarginine. cAMP response assays were performed as described in methods. The difference in activity between M-PTH(1-11) and PTH(1-11) is in line with previously noted structure-activity relationship studies⁴.



Supporting Figure 3. Assessment of antibody staining of HEK293 cells. HEK293 cells were stained with the mouse monoclonal antibodies at the indicated concentrations. Staining protocols are described in methods and antibodies used are detailed in Supporting Table 1. Data represent mean fluorescent intensity readouts in the indicated channels. Data shown are from a single representative experiment from three replicates. **(a)** Primary conventional antibodies were mixed at the doses indicated on the x-axis with VHH_{mIg}-biotin (here titled VHH_{Kappa}) conjugate (100 nM final concentration) and used to stain HEK293 cells. Antibody staining was detected using streptavidin-PE. Isotype control indicates polyclonal mouse IgG was used in place of a monoclonal mouse antibody. Streptavidin-PE indicates no primary antibody was used. **(b)** Primary conventional antibodies were used at the indicated concentration to label HEK293 cells. Primary antibody binding was detected with a secondary anti-mouse-Alexafluor647 conjugate.

References

- 1 M. J. Mahon, *Adv Biosci Biotechnol*, 2011, **2**, 132–137.
- 2 C. Lee, T. J. Gardella, A. B. Abou-Samra, S. R. Nussbaum, G. V. Segre, J. T. Potts, H. M. Kronenberg and H. Jüppner, *Endocrinology*, 1994, **135**, 1488–1495.
- 3 M. D. Luck, P. H. Carter and T. J. Gardella, *Mol Endocrinol*, 1999, **13**, 670–680.
- 4 N. Shimizu, J. Guo and T. J. Gardella, *J Biol Chem*, 2001, **276**, 49003–49012.